1. Home
  2. PCRX vs GGN Comparison

PCRX vs GGN Comparison

Compare PCRX & GGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pacira BioSciences Inc.

PCRX

Pacira BioSciences Inc.

HOLD

Current Price

$22.51

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

Logo GAMCO Global Gold Natural Resources & Income Trust

GGN

GAMCO Global Gold Natural Resources & Income Trust

HOLD

Current Price

$5.42

Market Cap

877.0M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
PCRX
GGN
Founded
2006
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Finance/Investors Services
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
877.0M
IPO Year
2010
N/A

Fundamental Metrics

Financial Performance
Metric
PCRX
GGN
Price
$22.51
$5.42
Analyst Decision
Strong Buy
Analyst Count
5
0
Target Price
$37.20
N/A
AVG Volume (30 Days)
579.3K
605.4K
Earning Date
05-07-2026
01-01-0001
Dividend Yield
N/A
10.26%
EPS Growth
107.44
N/A
EPS
0.16
N/A
Revenue
$541,533,000.00
N/A
Revenue This Year
$6.78
N/A
Revenue Next Year
$8.54
N/A
P/E Ratio
$139.00
N/A
Revenue Growth
26.04
N/A
52 Week Low
$18.80
$3.93
52 Week High
$27.99
$5.88

Technical Indicators

Market Signals
Indicator
PCRX
GGN
Relative Strength Index (RSI) 49.29 53.15
Support Level $22.57 $5.14
Resistance Level $23.94 $5.80
Average True Range (ATR) 0.79 0.14
MACD -0.07 0.04
Stochastic Oscillator 49.48 92.95

Price Performance

Historical Comparison
PCRX
GGN

About PCRX Pacira BioSciences Inc.

Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.

About GGN GAMCO Global Gold Natural Resources & Income Trust

GAMCO Global Gold Natural Resources & Income Trust is a non-diversified closed-end management investment company. Its primary investment objective is to provide a high current income and capital appreciation as its secondary objective. To achieve its objective, the fund may invest majority of its assets in equity securities of companies principally engaged in the gold and natural resources industries. It also intends to earn income through an option planning of writing (selling) covered call options on equity securities in its portfolio.

Share on Social Networks: